Research programme: 161533 TriKE fusion protein - GT Biopharma/Altor BioScience

Drug Profile

Research programme: 161533 TriKE fusion protein - GT Biopharma/Altor BioScience

Alternative Names: 161533; 161533 TriKE fusion protein; 161533 TriKE molecule; CD16/IL-15/CD33; CD16/IL-15/CD33 (161533) tri-specific killer cell engager (TriKE)

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Altor BioScience Corporation; OXIS International
  • Developer Altor BioScience Corporation; GT Biopharma
  • Class Antineoplastics; Immunotherapies; Proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Aug 2017 Oxis International is now called GT Biopharma
  • 07 Jul 2017 University of Minnesota plans a phase I/II trial for Haematological malignancies (CD33+, Second-line therapy or greater) in USA (IV, infusion) in USA in October 2017 (NCT03214666)
  • 21 Jun 2017 Oxis International and Altor BioScience agree to co-develop 161533 TriKE fusion protein for Haematologic malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top